Your browser doesn't support javascript.
loading
Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies.
Gopalakrishnan, Sathej; Mensing, Sven; Menon, Rajeev M; Zha, Jiuhong.
Afiliação
  • Gopalakrishnan S; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany.
  • Mensing S; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany.
  • Menon RM; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., Building AP31-3, 1 North Waukegan Rd., North Chicago, IL, 60064, USA.
  • Zha J; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., Building AP31-3, 1 North Waukegan Rd., North Chicago, IL, 60064, USA. jiuhong.zha@abbvie.com.
Clin Pharmacokinet ; 57(11): 1407-1419, 2018 11.
Article em En | MEDLINE | ID: mdl-29516428

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Hepatite C / Cirrose Hepática Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Hepatite C / Cirrose Hepática Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article